Boehringer Ingelheim Pharmaceuticals obtains dismissal of antitrust claims alleging sham litigation, brought by direct and indirect purchasers

Client(s) Boehringer Ingelheim Pharmaceuticals, Inc.

On behalf of Boehringer Ingelheim Pharmaceuticals, Inc., Jones Day obtained dismissal of direct and indirect purchaser class actions in cases alleging that Boehringer brought sham litigation to maintain an unlawful monopoly.

Carver v. Boehringer Ingelheim Pharmaceuticals, Inc., et al., No. 09-1044 (W.D. Pa.), and Meijer, Inc. v. Boehringer Ingelheim Pharmaceuticals, Inc., et al., No. 09-cv-01085 (W.D. Pa.)